Downloaded from http://bmjopen.bmj.com/ on November 14, 2015 - Published by group.bmj.com
Open Access
Research
Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis Robert Jackson,1 Aki Shiozawa,1 Erin K Buysman,2 Aylin Altan,2 Stephanie Korrer,2 Hyon Choi3
To cite: Jackson R, Shiozawa A, Buysman EK, et al. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open 2015;5: e007214. doi:10.1136/ bmjopen-2014-007214 ▸ Prepublication history for this paper is available online. To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-007214). Received 14 November 2014 Revised 18 March 2015 Accepted 13 April 2015
1
Takeda Pharmaceuticals International, Inc, Deerfield, Illinois, USA 2 Optum, Eden Prairie, Minnesota, USA 3 Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA Correspondence to Aki Shiozawa; [email protected]
ABSTRACT Objectives: For most gout patients, excruciatingly painful gout attacks are the major clinical burden of the disease. The goal of this study was to assess the association of frequent gout flares with healthcare burden, and to quantify how much lower gout-related costs and resource use are for those with infrequent flares compared to frequent gout flares. Design: Retrospective cohort study. Setting: Administrative claims data from a large US health plan. Participants: Patients aged 18 years or above, and with evidence of gout based on medical and pharmacy claims between January 2009 and April 2012 were eligible for inclusion. Patient characteristics were assessed during a 12-month baseline period. Outcome measures: Frequency of gout flares, healthcare costs and resource utilisation were assessed in the 12 months following the first qualifying gout claim. Generalised linear models were employed to assess the impact of flare frequency on cost outcomes after adjusting for covariates. Results: 102 703 patients with gout met study inclusion criteria; 89 201 had 0–1 gout flares, 9714 had 2 flares, and 3788 had 3+ flares. Average counts of gout-related inpatient stays, emergency room visits and ambulatory visits were higher among patients with 2 or 3+ flares, compared to those with 0–1 flares (all p
Open Access
Research
Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis Robert Jackson,1 Aki Shiozawa,1 Erin K Buysman,2 Aylin Altan,2 Stephanie Korrer,2 Hyon Choi3
To cite: Jackson R, Shiozawa A, Buysman EK, et al. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open 2015;5: e007214. doi:10.1136/ bmjopen-2014-007214 ▸ Prepublication history for this paper is available online. To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-007214). Received 14 November 2014 Revised 18 March 2015 Accepted 13 April 2015
1
Takeda Pharmaceuticals International, Inc, Deerfield, Illinois, USA 2 Optum, Eden Prairie, Minnesota, USA 3 Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA Correspondence to Aki Shiozawa; [email protected]
ABSTRACT Objectives: For most gout patients, excruciatingly painful gout attacks are the major clinical burden of the disease. The goal of this study was to assess the association of frequent gout flares with healthcare burden, and to quantify how much lower gout-related costs and resource use are for those with infrequent flares compared to frequent gout flares. Design: Retrospective cohort study. Setting: Administrative claims data from a large US health plan. Participants: Patients aged 18 years or above, and with evidence of gout based on medical and pharmacy claims between January 2009 and April 2012 were eligible for inclusion. Patient characteristics were assessed during a 12-month baseline period. Outcome measures: Frequency of gout flares, healthcare costs and resource utilisation were assessed in the 12 months following the first qualifying gout claim. Generalised linear models were employed to assess the impact of flare frequency on cost outcomes after adjusting for covariates. Results: 102 703 patients with gout met study inclusion criteria; 89 201 had 0–1 gout flares, 9714 had 2 flares, and 3788 had 3+ flares. Average counts of gout-related inpatient stays, emergency room visits and ambulatory visits were higher among patients with 2 or 3+ flares, compared to those with 0–1 flares (all p
